Safety
pyrexia, skin toxicity
ADVERSE EVENTS, ADVERSE EVENT, SKIN TOXICITY
Regardless of relation to study treatment, adverse events (AEs) were reported in 201 (97.6%) patients across all cohorts. The most commonly (≥20% of patients) reported AEs were pyrexia (Most frequent AEs (≥20%) by preferred termValues are number of patients, Preferred terms by MedDRA version 23.0 and CTCAE version 4.0.All treated patients (primary and expansion cohorts).AST, aspartate aminotransferase; MedDRA, Medical Dictionary for Regulatory Activities.Across all cohorts, 181 (87.9%) patients reported AEs (of any grade) that were related to the study treatment, either dabrafenib or trametinib. The most frequent (≥10% of patients) treatment-related AEs were pyrexia (Adverse events of special interest (AESIs) included skin toxicity (